The Association between lncRNA LINC01296 and the Clinical Characteristics in Neuroblastoma
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Sep 2019 · 1 min read
In brief
In brief
This study identifies LINC01296 as a significantly overexpressed long noncoding RNA in advanced-stage neuroblastoma, correlating with older age, larger tumor size, elevated tumor markers (LDH, NSE), and poorer overall survival. The findings suggest LINC01296 may serve as a prognostic biomarker for risk stratification in pediatric neuroblastoma patients.
Written by the GCMD Library team from the article.
Background
Neuroblastoma is the most common extracranial solid tumor in childhood. In this work, the clinical value of long noncoding RNA LINC01296 was evaluated in patients with neuroblastoma.
Methods
LncRNA microarray was conducted to identify differentially expressed lncRNAs in 5 early stage and 5 advanced stage tumor tissues of neuroblastoma. RT-qPCR was carried out to validate the result of microarray. Clinical information was reviewed to analyze the relationship between lncRNA and clinical characteristics. The public database R2 was used to analyze prognosis.
Results
765 differentially expressed lncRNAs were identified. LINC01296 was the most overexpressed lncRNA in advanced stage patients. RT-qPCR was conducted in 28 tumor tissues, confirming the tendency with microarray. Higher expression of LINC01296 was associated with age > 18 months (p = 0.004) and advanced stage (p = 0.021). Furthermore, LINC01296 was correlated with tumor size (r = 0.4060, p = 0.0321), LDH level (r = 0.6904, p = 0.0002), and NSE level (r = 0.5772, p = 0.0013). The neuroblastoma dataset shows patients with overexpression of LINC01296 obtained a shorter overall survival than low expression (n = 88, log-rank: P